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One hallmark of AIDS progression is a decline in CD4+ T lymphocytes, though the mechanism is poorly defined. There is ample evidence that
increased apoptosis is responsible for some, if not all, of the decline. Prior studies have shown that binding of cellular calmodulin to the envelope
glycoprotein (Env) of HIV-1 increases sensitivity to fas-mediated apoptosis and that calmodulin antagonists can block this effect. We show that
individual mutation of five residues in the C-terminal calmodulin-binding domain of Env is sufficient to significantly reduce fas-mediated
apoptosis in transfected cells. The A835W mutation in the cytoplasmic domain of gp41 eliminated co-immunoprecipitation of Env with
calmodulin in studies with stably transfected cells. Four point mutations (A835W, A838W, A838I, and I842R) and the corresponding region of
HIV-1 HXB2 were cloned into the HIV-1 proviral vector pNL4-3 with no significant effect on viral production or envelope expression, although
co-immunoprecipitation of calmodulin and Env was decreased in three of these mutant viruses. Only wild-type envelope-containing virus induced
significantly elevated levels of spontaneous apoptosis by day 5 post-infection. Fas-mediated apoptosis levels positively correlated with the degree
of calmodulin co-immunoprecipitation, with the lowest apoptosis levels occurring in cells infected with the A835W envelope mutation. While
spontaneous apoptosis appears to be at least partially calmodulin-independent, the effects of HIV-1 Env on fas-mediated apoptosis are directly
related to calmodulin binding.
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While increased apoptosis during HIV infection is a well-
documented phenomenon both in vitro (Katsikis et al., 1995)
and in vivo (Badley et al., 1998), its role in the pathogenesis of
AIDS remains controversial (Bell and Dockrell, 2003).
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Gatewood Rd, Atlanta, GA 30329, USA.of HIV infection is thought to be as high as 109 cells/day (Ho
et al., 1995), the fate of these cells remains undefined.
Hypotheses for this event include apoptosis (Alimonti et al.,
2003) direct cell killing by the virus (Cao et al., 1996) and
altered homing of lymphocytes to different immune compart-
ments (Alimonti et al., 2003; Cloyd et al., 2000) It is likely that
these all occur in vivo, and they may turn out to be related
events. Peripheral blood mononuclear cells (PBMCs), which
include CD4+ lymphocytes, from HIV-infected patients under-
go more spontaneous apoptosis than PBMCs from uninfected
donors (Pan et al., 1998). This increase in apoptosis correlates
with stage of disease (Cotton et al., 1997) and with fas
(Silvestris et al., 1996) and fas ligand (Badley et al., 1998)
expression, two proteins responsible for regulating physiolo-
gical apoptosis in lymphocytes (Mountz et al., 1994).6) 468 – 479
www.e
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receptor (TNFR) superfamily that transduces an apoptotic
signal following binding to fas ligand, (for review, see Peter et
al., 1999). This binding induces recruitment of proteins to the
death inducing signaling complex (DISC) (Scaffidi et al.,
1999). Included in the DISC are upstream initiator caspases,
including caspases 8 (Boatright et al., 2003) and 10 (Cohen,
1997), which are activated upon recruitment. This causes
activation of downstream effector caspases, including caspases
3, 6, and 7, release of cytochrome C from the mitochondria
(Green and Reed, 1998), cleavage of survival-promoting
proteins (Geng et al., 1998; Janicke et al., 1998), externaliza-
tion of phosphatidyl serine on the cell membrane (Denecker et
al., 2000), cell and nuclear shrinkage, DNA cleavage, and cell
death (Cidlowski et al., 1996). This simplified view of
apoptosis includes events that do not occur in every type of
apoptosis. Additionally, there is an opposing survival pathway
in operation at the same time (Gomez-Angelats et al., 2000),
and the relative strength of the two signals determines the
ultimate fate of the cell.
Within this expanding concept of apoptotic signaling is a
growing body of evidence that calcium (Krebs, 1998) and
calmodulin (Ahn et al., 2003) play a role in mediating
apoptosis. A slow, sustained increase in intracellular calcium
concentration has been observed in many types of apoptosis,
with calcium coming from both extracellular and intracellular
sources. Calcium channel blockers inhibit apoptosis (Ares et
al., 1997), and calcium release by thapsigargin can induce
apoptosis in certain cell types (Tombal et al., 2000). Calpain,
a calcium-dependent protease, has been shown to be active
during apoptosis (Ghibelli et al., 2003), and the endonuclease
responsible for the chromatin cleavage that occurs in most
forms of apoptosis is calcium-dependent (Yakovlev et al.,
2000). Death-associated protein (DAP) kinase is both
calcium- and calmodulin-dependent and functions in fas-
and TNFa-induced apoptosis downstream of receptor ligation
but upstream of effector caspases (Cohen et al., 1997). Other
calmodulin-dependent enzymes have proposed roles in
apoptosis, including calmodulin-dependent protein kinases
(CaM kinase) II (Wright et al., 1997) and IV (Means et al.,
1997) and the calmodulin-dependent phosphatase, calcineurin
(Ankarcrona et al., 1996). Calcineurin has been shown to
induce apoptosis by dephosphorylating the pro-apoptotic bcl-
2 homologue, bad (Wang et al., 1999), which subsequently
translocates to the mitochondria. Overexpression of calci-
neurin alone can induce apoptosis (Shibasaki and McKeon,
1995), and cyclosporine and FK506, which inhibit calcineurin
(Wiederrecht et al., 1993), can prevent many types of
apoptosis (Higashigawa et al., 1997). Recently, Ahn et al.
demonstrated that calmodulin binds to the cytoplasmic
domain of Fas and that this binding is altered during fas-
mediated apoptosis (Ahn et al., 2004).
HIV attachment and entry into cells occur through the
action of the viral envelope glycoproteins, gp120 and gp41.
The surface subunit of this Env complex is gp120, and the
transmembrane subunit (TM) is gp41. The binding and entry
process is multi-step and involves first the binding of gp120to the host CD4 molecule which allows gp120 to then bind
the chemokine receptor, CXCR4, on T cells (Choe et al.,
1998). The binding of the external subunit of envelope to the
host cell causes a conformational change that exposes the
external fusion domain of gp41 and allows viral entry
(Hunter, 1997). The cytoplasmic region of gp41 appears to
play an important role in viral assembly and infectivity, by
directing the glycoprotein to the correct subcellular location
(Nguyen and Hildreth, 2000) and by mediating interactions
between Env and the assembling capsid (Murakami and
Freed, 2000). The cytoplasmic tail of gp41 is approximately
150 amino acids long and is fairly well-conserved in different
strains of HIV-1 (Modrow et al., 1987). Especially well-
conserved are two calmodulin-binding domains near the C-
terminus of gp41 (Tencza et al., 1997). These regions are
predicted to form amphipathic helices, and peptides
corresponding to these regions bind to calmodulin (Srinivas
et al., 1993) and have been called lentiviral lytic peptides 1
and 2 (LLP1 and 2) based on their ability to lyse cells (Miller
et al., 1991). Expression of Env increases sensitivity to fas-
mediated apoptosis (Micoli et al., 2000) and has also been
reported to induce apoptosis in the absence of external stimuli
(Ishikawa et al., 1998).
Cells expressing full-length HIV Env, in contrast to those
expressing gp120 alone, display increased intracellular levels
of calcium that can be prevented by treatment with
calmodulin antagonists (Sasaki et al., 1996). The two highly
conserved calmodulin-binding regions of gp160/41 (Tencza
et al., 1997) were identified by homology to the calmodulin-
binding domain of myosin light chain kinase and confirmed
by peptide binding studies (Micoli et al., 2000; Srinivas et al.,
1993). Calmodulin has also been shown to associate with
gp160/gp41, but not with gp120 or various truncation mutants
of gp160/gp41 (Ishikawa et al., 1998; Radding et al., 1996).
Calmodulin expression increases in cells expressing Env with
intact calmodulin-binding domains, but not in cells expressing
truncated forms of Env or a point mutant that disrupts
calmodulin binding (Micoli et al., 2000; Radding et al.,
1996).
Expression of Env alone has been shown to increase
apoptosis induced by fas (Ishikawa et al., 1998), and this
could be blocked by calmodulin antagonists or by point
mutation of the C-terminal calmodulin-binding domain of
Env (Micoli et al., 2000; Pan et al., 1996). Additionally,
calmodulin antagonists reduce spontaneous apoptosis of
infected PBMCs cultured from AIDS patients (Pan et al.,
1998). Therefore, apoptosis may play a key role in the
progression of AIDS and one of the apoptotic triggers may
be the interaction between Env and calmodulin. However, the
precise molecular mechanism underlying the apoptotic events,
including upregulation of calmodulin by Env, remains to be
determined and represents a potentially useful area for the
development of new therapies for HIV-infected patients.
Furthermore, it is not known whether calmodulin binding to
Env plays a role in viral infectivity (Dubay et al., 1992) and/or
replication (Srinivas et al., 1994), processes clearly critical in
the pathogenesis of AIDS.
Fig. 2. Effect of gp41 point mutations on fas-mediated apoptosis in
transiently transfected Jurkat cells. The mutations shown in Fig. 1 were
placed in the vector pSRHS containing the cDNA for HIV-1 HXB2 gp160
Jurkat cells were transiently transfected then treated with 500 ng/ml anti-fas
(CH11) for 3 h. Apoptosis was quantified by TUNEL staining and manually
counting >300 cells/sample. The graph represents the mean percentage o
apoptotic cells, TSEM, of 3–6 independent experiments. Cells transfected
with an Env-expressing plasmid were significantly more fas-sensitive than
empty vector-transfected cells (P < 0.002), and all mutant-transfected cells
had significantly reduced fas sensitivity compared to Env-transfected cells
(P < 0.05).
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Effect of point mutation of gp160 on fas-mediated apoptosis
Our laboratory previously reported that expression of Env
enhanced fas-mediated apoptosis and that a single point
mutation in the C-terminal calmodulin-binding domain of
gp160/gp41, A835W, eliminated enhanced apoptosis (Micoli
et al., 2000). This mutation was chosen based on comparison
of the C-terminal calmodulin-binding domain of gp160 to the
calmodulin-binding domain of myosin light chain kinase
(MLCK), a model for calmodulin-binding proteins (see Fig.
1 for diagram of gp41 and selected point mutations). Four
other residues of gp160/gp41, alanine 838 and isoleucines
829, 839, and 842, corresponded to residues of MLCK that
make contact with calmodulin and were mutated to
isoleucine or tryptophan (A838) or arginine (I829, I839,
and I842). These mutants of gp160/gp41, as well as an
internal deletion mutant, DSD1, spanning residues 819–838,
were made in the envelope expression vector pSRHS and
transiently transfected into Jurkat cells to determine their
effect on fas-mediated apoptosis (Fig. 2). The transfected
cells were treated with 500 ng/ml anti-fas (clone CH11) for
3 h followed by TUNEL assay for apoptosis. Cells
transfected with wild-type Env underwent significantly more
apoptosis when treated with anti-fas (45 T 3%) than empty
vector-transfected cells (27 T 2%, n = 6, P < 0.001) or
EnvA835W-transfected cells treated with anti-fas (23 T 3%,
n = 6, P < 0.001). All of the mutants described above
showed significant reductions in fas-mediated apoptosis
compared to wild-type gp160: I829R (35 T 1%, n = 5, P <
0.03), A835I (26 T 1.7%, n = 3, P < 0.002), A838I (30 T
1.5%, n = 5, P < 0.003) A838W (33 T 1.4%, n = 4, P <
0.02), I839R (28 T 3%, n = 5, P < 0.003), I842R (34 T 2.5%,
n = 5, P < 0.02), and DSD1 (28 T 1.7%, n = 6, P < 0.001).Fig. 1. Diagram of gp41 and point mutants in the C-terminal calmodulin-
binding domain. Bar diagram of gp41, the transmembrane and cytoplasmic
subunit of gp160. The transmembrane region (black) and the N- and C-terminal
calmodulin-binding domains (cross-hatched boxes) are shown. The 30 amino
acids of the C-terminal binding domain are shown, with residues selected for
mutation in bold. The internal deletion DSD1 is also indicated..
fSpontaneous apoptosis was unaffected by the expression of
wild-type envelope or any of the envelope point mutations
compared to mock-transfected Jurkat cells (10 T 3%, n = 5).
Statistical analyses were performed using an unpaired t test with
Welch’s correction.
Effect of A835W mutation on calmodulin
co-immunoprecipitation with gp160/gp41
To determine the importance of gp160/gp41 binding
calmodulin on the enhancement of apoptosis, Jurkat Tet-off
cells stably transfected with wild-type Env or Env A835W
were incubated for 48 h with or without 2 Ag/ml
tetracycline to inhibit or induce, respectively, gp160 expres-
sion. We previously demonstrated that these two cell lines
expressed Env only when tetracycline was removed from the
culture medium and that apoptosis is unaffected by Env
expression in the absence of fas-stimulation in this time
frame (Micoli et al., 2000). Following induction of Env,
cells were labeled with 35S-cysteine/methionine, lysed, and
incubated with HIV+ patient serum to immunoprecipitate
Env. Following immunoprecipitation, proteins were separated
by SDS-PAGE, after which the gel was dried and
autoradiography performed to determine Env expression
(Fig. 3A, top). Alternatively, proteins were transferred
following SDS-PAGE and Western blotted for calmodulin
(Fig. 3A, bottom). Expression of wild-type and A835W
mutant Env was equivalent and was seen only in cells
incubated without tetracycline. Calmodulin strongly co-
immunoprecipitated with wild-type Env, but this interaction
was eliminated or greatly reduced by the A835W mutation.
Additionally, neither calmodulin nor envelope was co-
immunoprecipitated from cells incubated with tetracycline
to block expression of Env.
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co-immunoprecipitation
To determine what effect, if any, mutations of Env have on
calmodulin binding in the context of the entire virus, proviral
vectors were designed that inserted various Env point muta-
tions (illustrated in Fig. 1) into the pNL4.3 viral genome. These
were transfected into 293T cells to produce infectious virus,
which was collected and assayed for reverse transcriptase (RT)
activity. Approximately 5  104 RT units were then used to
infect 3  106 H9 cells, which were cultured for 28 days. At 3-
to 4-day intervals, cells were split to 3  106 cells/ml, and
aliquots of culture medium were assayed for RT activity. All of
the different viral constructs peaked between day 7 and day 11
post-infection (Fig. 4A).Cells infected as described above with HXB2 or the point
mutants A835W and A838W were lysed on day 7, 11, or 14
post-infection. HIV proteins were immunoprecipitated from the
cell lysates by HIV+ patient serum and separated by SDS-
PAGE. Following SDS-PAGE, the gel was cut at 35 kDa and
transferred for Western blot. The lower portion was probed for
calmodulin and the upper portion for Env. As shown in Fig.
3B, Env could be detected in equal amounts in samples from
all three viral constructs, but not from mock-infected samples.
In contrast, calmodulin strongly co-immunoprecipitated with
wild-type Env samples, but weakly with the Env mutants
A835W and A838W. Shown is a representative Western blot
from cells lysed on day 11 post-infection (n = 3). Similar
results were obtained using samples taken on days 7 and 14
post-infection (not shown).
In further experiments, cells were infected as described with
wild-type HXB2, A835W, A838I, and I842R, and cells were
collected and lysed on day 8 post-infection. A representative
Western blot shown in Fig. 3C indicates that gp120 production
was equivalent for all viruses and that, as in Fig. 3B, wild-type
HXB2 strongly co-immunoprecipitated with calmodulin while
A835W co-immunoprecipitation was greatly reduced. A838I
was also reduced in calmodulin co-immunoprecipitation, while
I842R co-immunoprecipitated calmodulin as strongly as
HXB2. The Western blots shown are representative of three
separate experiments and are similar to results obtained from
samples obtained on day 5 and day 12 post-infection (data not
shown).
The amount of calmodulin co-immunoprecipitated with
envelope was quantitated by densitometry (Fig. 3D) and shows
that the A835W mutation results in an 85% reduction in
calmodulin binding compared to HXB2 (P < 0.0001) and thatFig. 3. Effect of Env mutations on calmodulin co-immunoprecipitation. (A)
Jurkat Tet-off cells stably transfected with wild-type env (wild-type) or the
A835W env gene (A835W) were incubated in the presence of 2 Ag/ml
tetracycline (+Tet) to inhibit Env expression or in the absence of tetracycline
(Tet) for 48 h to induce expression of Env. Cells were metabolically labeled
with 35S-cysteine/methionine followed by immunoprecipitation with HIV+
patient serum. Immunoprecipitated proteins were separated by SDS-PAGE
and visualized by autoradiography for gp160/120 (upper panel) or by Western
blot for calmodulin (CaM) (lower panel). (B) H9 cells were infected as
described in panel A, and, on day 11 post-infection, approximately 1  106
cells were collected and lysed. Viral proteins were immunoprecipitated with
HIV+ patient serum, separated by SDS-PAGE, and Western blotted for gp120
(top) and calmodulin (bottom). Shown is a representative Western blot of two
independent experiments and is identical to results using cell lysates made on
day 7 and 14 post-infection (data not shown). (C) H9 cells were infected with
HIV-1 NL4-3 containing the env BamHI/XhoI fragments from HXB2. This
region was either unchanged (HXB2) or changed as indicated (A835W,
A838I, I842R). On day 8 post-infection, cells were lysed and viral proteins
immunoprecipitated as described in Materials and methods. Shown is a
representative Western blot (n = 3) and is similar to results obtained on days
5 and 12 post-infection (not shown). (D) Co-immunoprecipitation of
calmodulin with envelope was quantified by densitometry. For each mutation
of envelope tested, the band density corresponding to calmodulin was
determined, and this value was expressed as a percentage of the band density
from HXB2 Env-infected cells. Data shown are the means T SEM, n = 6 for
HXB2 and A835W and n = 3 for A838I, A838W and I842R. Asterisks
indicate a significant decrease in calmodulin co-immunoprecipitation com-
pared to HXB2 (P < 0.05).
Fig. 4. Effect of gp41 point mutations on HIV production in H9 cells infected
with HIV-1. (A) H9 cells were infected with HIV-1 NL4.3, NL4.3 with the
BamHI/XhoI fragment of wild type HXB2 env (HXB2) inserted, or NL4.3
containing the gp41 mutations A835W, A838W, A838I, or I842R. On day 10
post-infection, cells were collected and stained for gp120 by immunohisto-
chemistry (red), and with Hoechst dye to identify nuclei (blue). Shown is a
representative photomicrograph of three independent experiments. Identical
results were obtained in separate infections on day 7 post-infection (data not
shown). (B) H9 cells were infected as in panel A and at three day intervals
beginning on day 4 following infection, culture supernatants were collected and
assayed for reverse transcriptase (RT) activity. The mean RT activities of
triplicate samples are shown. (C) H9 cells were infected as in panel Awith env
point mutants A835W, A838I, and I842R. Cell culture supernatants were
collected at daily intervals following infection and viral p24 levels were
determined in triplicate by ELISA. Points represent averages of three
independent infections, TSEM.
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The A838I mutation reduced binding to calmodulin by 40%
and was significantly reduced compared to HXB2 (P < 0.05).
The I842R mutation retained the same ability to bind
calmodulin as HXB2.
The apparent differences in the amount of uncleaved gp160
immunoprecipitated (Figs. 3A–C) in HXB2-env-infectedsamples are due to different exposure times for each Western
blot. Longer exposures showed that uncleaved gp160 is
immunoprecipitated from all infected samples, and densito-
metric analysis of the gp160 band was not significantly
different between HXB2 and any of the mutants (data not
shown).
Effect of Env point mutations on HIV production
To verify that Env point mutants did not alter expression or
subcellular distribution of Env, cells were stained for gp120 by
immunofluorescence (Fig. 4A) after infection. Shown is a
representative photomicrograph of H9 cells infected with HIV
encoding wild-type Env or the listed Env point mutants on day 7
post-infection following staining for gp120 (red). Nuclei were
stained with Hoechst to demonstrate total cell number. As
shown, on day 7 post-infection, all cells express approximately
equal amounts of gp120 expression (red staining). Staining
performed on days 5 and 10 post-infection also had equal gp120
staining in all constructs tested, and no envelope staining was
detected on days 1 or 3 post-infection (data not shown).
To determine what effect, if any, mutations of Env have on
viral production, proviral vectors were designed that inserted
various Env point mutations (illustrated in Fig. 1) into the
pNL4.3 viral genome. These were transfected into 293T cells to
produce infectious virus, which was collected and assayed for
reverse transcriptase (RT) activity. Approximately 5  104 RT
units were then used to infect 3  106 H9 cells, which were
cultured for 28 days. At 3- to 4-day intervals, cells were split to
3  106 cells/ml, and aliquots of culture medium were assayed
for RT activity. All of the different viral constructs peaked
between day 7 and day 11 post-infection (Fig. 4B).
In later experiments, verification that the point mutations
did not cause defects in viral production was shown by p24
assay (Fig. 4C). Production of p24 was monitored by ELISA
on the culture supernatants of virally infected cells on each day
for 12 days post-infection. In all cases, p24 production was
substantial by day 2 post-infection, increasing to peak values
between days 7 and 8 post-infection. These data indicate that
HIV production was not significantly impaired by any of the
point mutants. In fact, p24 values were higher for the A835W
and A838I mutants than for the I842R mutation or wild-type
envelope-containing virus prior to reaching peak values. After
day 8, levels of p24 dropped slightly and remained at the same
level for the duration of the experiment, with no difference
among the mutants and wild-type viruses.
Effect of Env point mutations on spontaneous apoptosis
following HIV infection
H9 cells were infected with HIV as described above, and
apoptosis was determined on day 5 post-infection. Spontaneous
apoptosis was determined in the absence of activating fas
antibody treatment and on day 5 post-infection. Significantly
elevated levels of apoptosis were seen only in cells infected
with WTHXB2, 13% versus 9% in mock-infected cells, P <
0.01 (39.6% increased apoptosis) (Fig. 5A).
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following HIV infection
Fig. 5B demonstrates the effect of HIV-1 infection of H9
cells on fas-mediated apoptosis 5 days post-infection. On day 5
post-infection, 1  106 cells were treated for 1 h with 500 ng/
ml anti-fas to induce apoptosis followed by fixation and
Hoechst staining for apoptosis. Fas-mediated apoptosis was
calculated by subtracting spontaneous apoptosis values from
apoptosis values measured after treatment with activating fas
antibody for each sample. The axis break in Fig. 5B is to better
illustrate the difference in apoptosis levels and does not reflect
subtraction of spontaneous apoptosis. Cells infected with HIV
encoding wild-type Env had significantly higher levels of
apoptosis than mock-infected cells (74% increase, 31%
apoptotic cells versus 18% in mock-infected cells, P < 0.02).
The Env mutant I842R enhanced fas-mediated apoptosis 60%
above mock-infected cells, P < 0.02. In contrast, infection withFig. 5. (A) Spontaneous apoptosis in H9 cells infected with HIV-1. H9 cells
were infected with HIV-1 NL4.3 with the BamHI/XhoI fragment of the wild-
type HXB2 env gene (WTHXB2) inserted or the same viral construct
containing the indicated point mutations in gp41. Spontaneous apoptosis was
determined on day 5 post-infection by Hoechst staining and morphological
analysis of nuclei. Shown are the results of three independent infections,
indicating mean percentage of apoptotic cells TSEM. (B) Fas-mediated
apoptosis in H9 cells infected with HIV-1. H9 cells were infected with HIV-
1 NL4.3 with the BamHI/XhoI fragment of the wild-type HXB2 env gene
(WTHXB2) inserted or the same viral construct containing the indicated point
mutations in gp41. Cells were treated with 500 ng/ml anti-fas on day 5 post-
infection for 1 h followed by fixation and Hoechst staining and morphological
analysis of nuclei. Fas-mediated apoptosis was calculated by subtracting the
value for spontaneous apoptosis from the value for apoptosis following fas
antibody treatment. Data represent the mean percentage of apoptotic cells from
three independent experiments, TSEM.the A835W mutant resulted in levels of fas-mediated apoptosis
that were not significantly elevated above mock-infected levels
(10% increase). The levels of fas-mediated apoptosis in the
A835W-infected cells (20 T 1.5%) were significantly lower
than in wild-type-infected cells (31.7 T 2.6%), P < 0.02. The
effect of the A838I mutation on fas-mediated apoptosis was
intermediate, with lower apoptosis levels compared to wild-
type (25% vs. 31% P > 0.05, N.S.), and although this level of
apoptosis was higher than the levels in mock-infected cells
(increased by 40%), the difference was not statistically
significant (P > 0.05). Apoptosis levels after fas antibody
treatment did not change on day 12 post-infection in any of the
infected cells, despite increases in spontaneous apoptosis in all
of the infected cells (data not shown).
Discussion
While it has been known for some time that HIV infection
leads to a depletion of the CD4+ lymphocytes and that this
depletion is a major component of the eventual failure of the
immune system, the mechanism of this loss remains contro-
versial (Alimonti et al., 2003). Apoptosis of infected and
uninfected cells in the immune system is one possible
mechanism, and there is abundant evidence indicating that this
occurs both in vitro and in vivo (Cotton et al., 1997). The
mechanism of HIV-induced apoptosis is also controversial as
multiple HIV proteins possess the ability to induce or enhance
apoptosis, including envelope (gp160) (Ishikawa et al., 1998;
Micoli et al., 2000), Tat (Bartz and Emerman, 1999), Vpr (Jian
and Zhao, 2003; Shostak et al., 1999), Nef (Zauli et al., 1999),
Vpu (Casella et al., 1999), and Rev (Trillo-Pazos et al., 2000).
Two of these proteins, Tat (McCloskey et al., 1997) and Vpr
(Fukumori et al., 1998), have been shown to possess anti-
apoptotic properties as well.
Calmodulin, the major cellular calcium sensing and binding
protein, has been reported in numerous systems to play a role in
apoptotic signaling (Ahn et al., 2004), and two HIV proteins
besides envelope, Gag (Radding et al., 2000) and Nef (Hayashi
et al., 2002), have been shown to bind calmodulin, adding
further complexity to the issue. Additionally, the cytoplasmic
tail of HIV-1 gp41 contains two well-conserved domains that
bind calmodulin (Tencza et al., 1997). These domains have
been identified by peptide studies and by comparison to the
calmodulin-binding domain of skeletal muscle myosin light
chain kinase (Micoli et al., 2000). Truncation of the cytoplas-
mic tail of gp41 reduced the sensitivity of T cells to fas-
mediated apoptosis (Pan et al., 1996), and one point mutant in
the C-terminal calmodulin-binding domain eliminated both
enhanced apoptosis and calmodulin binding to a synthetic
peptide with that mutation (Micoli et al., 2000). We therefore
created a panel of point mutants predicted to prevent
calmodulin binding and tested their effect on apoptosis (Fig.
2). All of these Env mutants led to a significant decrease in fas-
mediated apoptosis compared to wild-type Env when expressed
in transiently transfected Jurkat cells, strengthening the
hypothesis that this region of Env is critical for this effect.
Expression of Env in the absence of fas stimulation did not
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tested by TUNEL assay, Trypan blue exclusion, and annexin
V-FITC staining (data not shown), indicating that the levels of
Env expression in this model are not sufficient to grossly alter
membrane permeability. The data presented in this manuscript
indicate that the more C-terminal calmodulin-binding domain
plays a critical role in binding calmodulin since mutating either
A835 or A838 to W eliminates co-immunoprecipitation of Env
and calmodulin (Fig. 3).
Although the C-terminal domain appears to be the more
important for binding calmodulin, these experiments cannot rule
out the possibility that both calmodulin-binding domains are
necessary for binding. However, the N-terminal calmodulin-
binding domain may be too constrained in the context of the
entire gp41 protein to form a helix in vivo (Srinivas et al., 1993)
and thus may not be able to bind calmodulin. This hypothesis is
strengthened by work with the SIV calmodulin-binding domain
using NMR and circular dichroism that indicated the helical
nature of the region increased upon addition of calmodulin and
that this interaction appeared to be in a 1:1 ratio (Yuan et al.,
1995). Nevertheless, higher order multimers were also detected,
and the possibility that more than one calmodulin molecule was
binding to each gp41 molecule could not be ruled out.
It is interesting that disruption of the calmodulin-binding
domain did not diminish viral infectivity or Env production
(Fig. 3). However, as HIV-1 is able to replicate efficiently in
vitro with many other mutations, including deletion of entire
genes, the in vitro assay system utilized here may not be
sufficiently sensitive to detect subtle changes in viral fitness. It
will be of interest to determine whether the point mutations
tested in these studies have a detrimental effect on viral
production in vivo in the SHIV animal model.
Despite the fact that none of the point mutations in gp41 led
to a significant impairment of viral production in vitro, several
of these mutations did significantly reduce HIV-enhanced fas-
mediated apoptosis (Fig. 5). Interestingly, although spontane-
ous apoptosis significantly increased over time with all of the
infectious virus constructs, fas-mediated apoptosis was virtu-
ally unchanged from day 5 compared to day 12 post-infection
(Fig. 5 and data not shown). This indicates that the molecular
events necessary to fully enhance fas-mediated apoptosis occur
early in infection and are maintained at the same level over
time despite large increases in viral production (Fig. 3). In fact,
the point mutant A835W reduced fas-mediated apoptosis to the
level of mock-infected cells on day 5 post-infection. The data
implicate gp160/gp41 as the major factor enhancing fas-
mediated apoptosis in HIV-infected cells. Importantly, the
results suggest that there is a direct link between the ability of
gp160/gp41 to bind calmodulin and enhance fas-mediated
apoptosis as A835W which co-immunoprecipitates little or no
calmodulin (Fig. 4) has an apoptotic profile identical to
mock-infected cells (Fig. 5), and I842R, which co-immuno-
precipitates calmodulin at levels equal to wild-type HXB2,
has an apoptotic profile identical to that virus. The A838I
mutant, which shows an intermediate apoptotic phenotype,
was also intermediate in its ability to co-immunoprecipitate
calmodulin.The issue of whether infected or uninfected (bystander) cells
undergo apoptosis during natural infection is very important
but could not be addressed by the studies reported here.
Staining for envelope and observing nuclei for apoptotic
morphology were inconclusive as envelope expression was
observed in all cells at all time points where apoptosis levels
increased (Figs. 4A and 5).
A significant amount of uncleaved gp160 was immunopre-
cipitated from infected cells, and it is not known whether this
form of Env plays a role in apoptosis since uncleavable Env
mutants do not produce infectious virus.
It is not currently known, and beyond the scope of these
investigations, whether the pro-apoptotic effects of gp160/gp41
are mediated by increasing or decreasing calmodulin signaling.
We have shown previously that expression of full-length Env,
but not A835W or D147 Env, leads to increases in calmodulin
expression (Micoli et al., 2000; Radding et al., 1996). This
raises the possibility that pro-apoptotic calmodulin-binding
proteins are more active in this situation and that the increase in
calmodulin expression may by the key event in enhancing
apoptosis by HIV. Calmodulin-dependent enzymes, most
notably calcineurin, have been shown to play important roles
in apoptotic signaling (Ankarcrona et al., 1996). Increased
calmodulin expression could lead to increased activity of
calcineurin, which has been shown to cause apoptosis in certain
cell types (Shirane and Nakayama, 2003; Tombal et al., 2000).
Calcineurin can activate the pro-apoptotic protein bad by
dephosphorylation (Wang et al., 1999), inducing bad to
translocate from the cytosol to the mitochondrial membrane
where it presumably interferes with bcl-2 function. Calcineurin
also functions in activating NF-AT (nuclear factor of activated
T cells) (Rao et al., 1997), a transcription factor that can
increase expression of fas ligand (Latinis et al., 1997).
Upregulation of fas ligand (Badley et al., 1996) and its
receptor, fas (McCloskey et al., 1998), have been observed in
HIV-infected individuals, and this upregulation correlates with
increased apoptosis and disease progression.
It has also been speculated that the binding of gp41 to
calmodulin may disrupt anti-apoptotic calmodulin signaling in
the cell by either reducing the amount of free calmodulin in
the cytoplasm or altering its subcellular localization (Srinivas
et al., 1993). The recent report that calmodulin binds directly
to fas in the absence of stimulation raises the possibility that
calmodulin functions to negatively regulate fas signaling (Ahn
et al., 2004). This scenario is strengthened by data showing
that calmodulin binding to fas is increased immediately
following activation of fas but that with further incubation
with activating antibody, binding is diminished. The fact that
calmodulin binds both gp160/gp41 and fas and that gp160/
gp41 enhances fas-mediated apoptosis strengthens the hy-
pothesis that enhanced apoptosis may be due to altered
localization of calmodulin.
Changes in calmodulin expression and localization can
also impact calcium regulation in cells as calmodulin binds to
and modulates the activity of the plasma membrane calcium
pump (Carafoli et al., 1986), the ryanodine receptor, RYR1
(Rodney et al., 2000), and the IP3 receptor (Hirota et al.,
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The interaction between calmodulin and these proteins is
calcium-dependent, and the effect of calmodulin on the
ryanodine receptor changes from activation to inhibition with
increases in calcium. Both RYR1 and the IP3 receptor have
been shown to have roles in mediating apoptosis (Diaz and
Bourguignon, 2000; Hajnoczky et al., 2000). Increased
cytosolic calcium is seen in multiple cell types undergoing
apoptosis (Tombal et al., 2000), and there is good evidence
that the calcium-dependent protease calpain plays a role in
apoptosis as well (Johnson, 2000).
Overall, the data presented here indicate that calmodulin
binding to gp160/gp41 is necessary for enhanced fas-mediated
apoptosis in two transfection models and in cells infected with
HIV-1. The data show that point mutations in the C-terminal
calmodulin-binding domain of Env diminish calmodulin
binding and apoptosis, indicating a possibility that interruption
of the interaction of gp160/gp41 with calmodulin by pharma-
ceutical means could lead to a disruption of the sequence of
events leading to the CD4+ lymphocyte depletion and immune
system failure characteristic of AIDS.
Materials and methods
Cells and cell culture
Jurkat and H9 cells were purchased from the ATCC
(Rockville, MD) and grown at 37 -C in 5% CO2 in RPMI
1640 medium supplemented with 10% heat-inactivated fetal
bovine serum, 100 U/ml penicillin, 100 Ag/ml streptomycin,
and 2 mM l-glutamine.
Plasmids
Plasmid pSRHS containing the HIV-1 envelope gene
encoding gp160, and the truncated forms of gp160, D147,
which lacks the C-terminal 147 amino acids of gp41, and D67,
which lacks the C-terminal 67 amino acids of gp41, the
plasmid pKS8, containing the cDNA for h-galactosidase under
control of the human h-actin promoter, and the HIV-1 proviral
construct pNL4.3 containing the BamHI/Xho fragment of
HXB2 envelope have been previously described (Piller et al.,
2000) and were used in all transfection and infection
experiments.
Transfections
All transient transfections were performed using the cationic
lipid, DMRIE-C (Gibco-BRL, Rockville, MD). Briefly, lipid/
DNA complexes were allowed to form for 45 min at room
temperature in serum-free medium. Cells were added to the
complex in serum-free medium and incubated for 5 h at 37 -C
in 5% CO2. RPMI 1640 medium (Gibco-BRL) was added, and
cells were cultured an additional 48 h. Transfection efficiency
was monitored by simultaneous transfection of the h-galacto-
sidase expression vector, pKS8. Efficiencies ranged from 50 to
90% in Jurkat cells.Antibodies and reagents
Monoclonal antibody to calmodulin was developed as
previously described (Sacks et al., 1991; now available
from Upstate Biotechnology Inc. Lake Placid, NY). Mouse
anti-human fas monoclonal antibody CH11 (Upstate Bio-
technology Inc.) was used to induce apoptosis. Mouse anti-
gp120 Mab (ID6) was used for immunohistochemistry, and
sheep antiserum to HIV-1 IIIB was used for gp160/120
Western blot, both obtained from NIH AIDS Research and
Reference Reagent Program (Rockville, MD). HIV immu-
noprecipitation was performed with pooled sera from HIV+
patients.
Site-directed mutagenesis
Stratagene’s (La Jolla, CA) Quikchange Site-directed
Mutagenesis Kit was used to make point mutations of gp160
according to manufacturer’s instructions. Primers for the
mutagenesis were purchased from Gibco-BRL and correspond
to the desired mutations of I829 to R, A835 to W or I, A838 to
Wor I, I839 to R, and I842 to R flanked by 10–15 base pairs of
correct sequence, using the sequence of HIV-1 strain HXB2 as
a template.
Creation of gp160 and gp160A835W expressing cell lines
Tet-off Jurkat cells (Clontech, Palo Alto, CA) were
transfected with the pTRE expression vector containing
gp160 or gp160A835W cDNA by electroporation. Selection
of stable cell lines was initiated 48 h after transfection using
100 Ag/ml G418 (Gibco BRL), 300 Ag/ml hygromycin, and 2
Ag/ml tetracycline in RPMI 1640 complete medium changed
every 4 days. After 5–7 days, living cells were separated from
dead cells by Ficoll–Hypaque centrifugation and plated at a
lower density. After serial dilution, isolated single cell clones
were cultured in 96-well plates then transferred to 75 cm2 tissue
culture flasks.
TUNEL staining
In situ apoptosis staining was performed using terminal
deoxynucleotide transferase (Boehringer Mannheim, Indiana-
polis, IN). Briefly, cells were collected and cytospun onto
microscope slides and fixed in 10% formalin in PBS. Samples
were washed and treated with 20 Ag/ml Proteinase K (Fisher,
Pittsburgh, PA) for 15 min at room temperature followed by
several washes with water and incubated at 37 -C with TdT
(0.3 U/ml), digoxigenin-labeled dUTP, and buffer (30 mM Tris
base, pH 7.2, 140 mM sodium cacodylate, 1 mM cobalt
chloride). After a brief wash, samples were blocked in 1%
BSA, 0.1% gelatin in PBS for 15 min at room temperature.
Samples were incubated with alkaline-phosphatase-conjugated
anti-digoxigenin antibody for 1 h at room temperature, washed
in PBS, and developed with NBT/BCIP (Sigma, St. Louis,
MO) at room temperature for 30 min. Following development,
cells were counted, scored as apoptotic or non-apoptotic, and
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Hoechst staining
Following HIV infection, cells were fixed in 10% buffered
formalin overnight, cytospun onto slides, washed 3 in PBS,
and incubated in 10 Ag/ml bisbenzimide (Sigma) in PBS for 1
min. Slides were washed 3 with PBS, mounted, and
coverslipped. Apoptosis was determined by microscopic
evaluation of nuclei, with at least 250 cells/slide counted and
scored.
Immunoprecipitation and Western blot for calmodulin and Env
Cells were treated as indicated and lysed in buffer
containing 50 mM HEPES, pH 7.4, 150 mM NaCl, 0.5%
NP-40, 1 mM sodium orthovanadate, 1 mM EGTA, 1 mM
ammonium molybdate, 50 mM NaF, 0.5 AM okadaic acid, 5
mM benzamidine, and 50 Ag/ml pepstatin. After brief
centrifugation at 3000  g to remove debris, approximately
500 Ag of protein was incubated with 1 Al HIV patient serum
for 1–3 h at 4 -C with rotation. In addition to protein assay
to determine protein levels in the cell lysates, total protein
was assessed by Coomassie stain of the post-transfer gels, and
total calmodulin was determined by Western blot for
calmodulin in the post-IP supernatants. Immunoprecipitated
proteins were pulled down using Protein A–agarose (60 Al of
1:1 slurry) or an equivalent amount of heat-inactivated
Staphylococcus aureus. After four washes with lysis buffer
and one wash with TBS, immunoprecipitated proteins were
separated on 12.5% SDS-PAGE and transferred to Immobilon
P membrane (Millipore, Bedford, MA). Membranes were
fixed in 0.2% glutaraldehyde in Tris-buffered saline (TBS) for
calmodulin only, blocked in TBS containing 2% BSA and
0.2% gelatin, and then incubated with a monoclonal
calmodulin antibody (1:3000) in TBS–Tween 20 (TTBS)
and anti-mouse–HRP-conjugated antibody (Amersham, Pis-
cataway, NJ), 1:5000 in TTBS followed by development with
enhanced chemiluminescence (ECL; Amersham). For gp160
Western blot, membranes were incubated with sheep anti-
gp120 antibody at 1:1000 in TTBS followed by anti-sheep–
HRP antibody and development by ECL.
Densitometric analysis
Quantitation of co-immunoprecipitated calmodulin was
performed using densitometry by the following method. Films
were scanned and converted to TIFF images. Using Adobe
Photoshop Elements, the image was inverted, and bands were
selected and analyzed for average pixel luminescence. A
sample of identical size in an adjacent region was analyzed
and subtracted as background for each lane. To normalize
densitometric ranges, the band density for mock-infected cells
was subtracted from all samples, and the value from HXB2-
infected cells was set as 100%. Band density for each Env
mutation-infected sample was expressed as a percent ofHXB2 band density, and the mean T SEM was determined.
Statistical analysis was performed using a one-tailed, paired t
test.
Infection of H9 cells with HIV-1
Proviral constructs encoding wild-type pNL4.3 or various
envelope mutations were transfected into 293T cells using
Fugene 6 (Roche Applied Science, Indianapolis, IN). Forty-
eight hours post-transfection, cell culture supernatants were
collected and filtered (0.45 Am), and viral activity measured by
reverse transcriptase (RT) or p24 assay. Approximately 5  104
RT units were used to infect 3  106 H9 cells. Briefly, H9 cells
were counted, collected by centrifugation (1000  g for 5 min),
and resuspended in 5 ml media (RPMI, 10%FBS, pen/strep)
containing 5  104 RT units. After overnight incubation, cells
were collected and resuspended in 10 ml fresh media. Cells
were counted and culture supernatant collected on the indicated
days for RT determination.
In other infections, DNA transfections were performed on
60–70% confluent monolayer culture of 293T cells grown in
six-well plates using FuGENE 6 Transfection Reagent (Roche
Applied Science) in accordance to manufacturer’s protocol.
Supernatants from transfected cultures were collected 72 h post-
transfection, clarified by low-speed centrifugation (1000–
1500  g, 15 min), filtered through 0.45 Am low protein
binding filters (Pall Corporation, East Hills, NY), aliquoted and
stored at 80 -C.
HIV-1 p24 antigen concentration was determined by
enzyme-linked immunosorbent assay (ELISA) (Beckman-
Coulter Inc., Fullerton, CA).
Infectious titers of the viral stocks were determined by
infecting JC53 BL cells with serial five-fold dilutions in the
presence of DEAE-dextran (40 Ag/ml) during 2 h at 37 -C.
Cells were cultured in Dulbecco’s modified Eagle medium
containing 10% fetal bovine serum (FBS), 100 U/ml of
penicillin, and 100 Ag/ml of streptomycin. After 2 days in
culture, cells were fixed and stained to detect h-Gal expression
as described (Piller et al., 2000).
H9 cells were infected with equal amounts of the viral
stocks (MOI = 0.5 IU/cell) in RPMI 1640 medium containing
1% FBS and 8 Ag/ml of Hexadimethrin Bromide (formerly
Polybrene, Sigma) during 4 h at 37 -C. After that, cells were
washed two times with Hank’s solution and cultured in RPMI
1640 medium supplemented with 10% FBS, 100 U/ml of
penicillin, and 100 Ag/ml of streptomycin. Cells were split 1:2
every 3–4 days, and fresh medium was added. Aliquots of the
culture supernatants were taken every 24 h and kept at 80 -C
for further analysis of HIV-1 p24 concentration.
Reverse transcriptase (RT) assay
RT activity in culture supernatants was assayed by taking 25
Al culture supernatant from infected cultures and incubating
with 75 Al reaction mix composed of 67 mMTris–HCl (pH 8.0),
6.7 mM dithiothreitol, 6.7 mM MgCl2, 200 mM KCl, 0.133%
Triton X-100, 0.67 mM EGTA, 5 ACi 35S-TTP (10 mCi/ml),
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90 min at 37 -C then stopped by addition of 50 Al of 200 mM
NaPPi and blotted onto NA45 paper (Schleicher and Schuell,
Keene, NH). The samples were quantitated by a radioanalytical
imaging system (AMBIS Systems Inc., San Diego, CA).
HIV-1 p24 antigen assay
Production of HIV was also monitored by p24 assay
(Beckman Coulter) following the manufacturer’s instructions.
Briefly, aliquots of cell culture conditioned medium were
collected at various time points following infection with HIV-1
pNL4.3, beginning on day 1 and continuing at 3- to 4-day
intervals until day 18 post-infection. Culture supernatant was
diluted with RPMI 1640 (1:10–1:10,000) and added to HIV-1
p24 antibody-coated microtiter plates with lysis buffer for 1 h.
Plates were washed six times with wash buffer supplied by
manufacturer followed by incubation for 1 h with biotinylated
anti-HIV IgG. Following incubation with streptavidin/horse-
radish peroxidase, color was developed with tetramethylbenzi-
dine (TMB) and hydrogen peroxide. The reaction was stopped
with 4N H2SO4, and A450/570 was determined. Actual ng/ml
p24 values were determined by plotting sample values on a
standard curve of known p24 quantities.
Immunofluorescence for gp120
Expression of gp120 was verified in HIV-infected cells on
various days post-infection by immunofluorescent staining.
Cells were fixed and spun onto slides then incubated in 2%
BSA in PBS for 30 min. Primary antibody was a monoclonal
anti-gp120 (ID6) and was diluted 1:200 in PBS prior to 1-h
incubation with slides. Following 6 washes (1 min each) in
PBS, slides were incubated with a goat anti-mouse antibody
(1:200 dilution) conjugated to Alexafluor 594 (Invitrogen,
Molecular Probes, Carlsbad, CA) for 30 min. Slides were
washed, mounted under coverslips with anti-fade mounting
medium, and analyzed by fluorescence microscopy.
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